Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
sha** cancer immunosurveillance and response to immunotherapy. Our understanding of …

Background Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients
with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

Background Neoadjuvant chemotherapy and radiation followed by surgical resection of the
rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite
recent advancements, most patients die of their disease. Although immune checkpoint …

Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4,
administered alone or in combination with chemotherapy, are the standard of care in most …